Ginkgo Bioworks Holdings, Inc. vs. Moderna, Inc. Common Stock
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| DNA | MRNA | |
|---|---|---|
| Market Cap | $468.69 million | $53.23 billion |
| Revenue (TTM) | $111.86 million | $2.23 billion |
| Net Income (TTM) | $-290,803,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| DNA | MRNA | |
|---|---|---|
| Price / Book | 1.12 | 7.87 |
| Price / Sales | 4.19 | 23.89 |
DNA leads on 2 of 2 valuation factors.
Profitability
| DNA | MRNA | |
|---|---|---|
| Net Margin | -259.96% | -141.43% |
| Return on Equity | -69.19% | -46.61% |
MRNA leads on 2 of 2 profitability factors.
Risk & Sentiment
| DNA | MRNA | |
|---|---|---|
| Short Interest | 18.73% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: DNA overview, DNA financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.